Skip to Primary Navigation

Skip to main content

SEC settles insider trading case with Massachusetts resident involving Sage Therapeutics

The agency alleged that Brian Suthoff liquidated all of his Sage stock in advance of negative news.

Article label: Quick Read
Premium article

Kevin Kinsella

Photo of the agency seal on exterior side of the Securities and Exchanges Commission building
Photo: Anna Moneymaker/Getty Images
Click to share on Facebook (Opens in new window/tab) Click to share on X (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The SEC has resolved insider trading allegations with a Massachusetts resident concerning Sage Therapeutics, Inc, after his alleged liquidation of shares in the company on the basis of “extremely restricted” FDA-related information.

According to the SEC’s complaint, Brian Suthoff allegedly avoided losses of nearly $20,000 by trading in advance of

, , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial
Sign in

What’s included:

  • Every new article, plus our 6,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience